花旗将10x Genomics(TXG.US)评级下调至持有,目标价上调至18美元
Citi Downgrades 10x Genomics(TXG.US) to Hold Rating, Raises Target Price to $18 - 富途牛牛
生物技术与制药领域的最新动态
Citi Downgrades 10x Genomics(TXG.US) to Hold Rating, Raises Target Price to $18 - 富途牛牛
Cytiva and Fida Biosystems Collaborate to Enhance Protein Analysis Techniques - Zenopa
AC Immune posts positive data for Parkinson’s immunotherapy
Citi Upgrades Thermo Fisher Scientific (TMO) to Buy, Raises Pric - GuruFocus
What's Driving the Market Sentiment Around Agilent Technologies Inc? - Benzinga
Thermo Fisher Scientific (TMO) valuation after fresh Wall Street upgrades and Asia bioprocessing expansion - simplywall.st
Why 10x Genomics (TXG) Stock Is Nosediving - Finviz
Financings for Dec. 11, 2025
In the clinic for Dec. 11, 2025
Other news to note for Dec. 11, 2025
Regulatory actions for Dec. 11, 2025
Petition claims FDA oops! means COVID-19 vaccines misbranded
10x Genomics downgraded to Neutral from Buy at Citi - TipRanks
Biotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backer
Why 10x Genomics (TXG) Stock Is Nosediving - TradingView — Track All Markets
Why 10x Genomics (TXG) Stock Is Nosediving - Yahoo Finance
Why 10x Genomics (TXG) Stock Is Nosediving - Markets Financial Content
Umoja delays first readout for in vivo CAR-T therapy
Rezolute crashes as its only drug fails in Phase 3
Rhythm reports Imcivree’s key weight loss data from Phase 2 Prader-Willi trial